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Abstract: A number of drugs rely on the kidney for excretion and thus require their dose to be 
modiﬁ  ed in any patients where there is renal impairment. Others are nephrotoxic and should be 
avoided completely in patients with renal disease. Traditionally clinicians have had to rely on 
serum creatinine to assess renal function but this may not accurately reﬂ  ect the kidney function 
of an individual since its level also depends on muscle mass. In particular elderly females may 
have signiﬁ  cant impairment of renal function despite a normal or near normal serum creatinine. 
The advent of automated reporting of estimated glomerular ﬁ  ltration rate (eGFR) provides 
the clinician with simple, easily understood and readily available measurement which more 
accurately reﬂ  ects a patient’s renal function. In particular eGFR allows the clinician to readily 
identify and stratify patients with chronic kidney disease (CKD) and can allow a more rational 
and safer approach to prescribing in this group of high risk patients. This commentary suggests 
that national prescribing formularies should use eGFR to provide consistent advice about the 
appropriate dose adjustment and avoidance of potentially toxic drugs at various stages of CKD. 
Such an approach may prove invaluable in improving prescribing in CKD and avoiding drug 
toxicity in this group of patients.
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The “gold standard” measurement for assessment of renal function is glomerular ﬁ  ltra-
tion rate (GFR). The normal range is 90–120 ml/min/1.73 m2 and hence it provides easy 
to interpret information for the doctor and patient on the degree of renal impairment 
since it approximately equates to the percentage of kidney function remaining.
The international 5 stage classiﬁ  cation of chronic kidney disease (CKD) developed 
by the US National Kidney Foundation in their Kidney Disease Outcomes Quality 
Initiative (KDOQI 2002) (Table 1) has now been widely adopted by nephrologists. 
The classiﬁ  cation is based on the level of GFR for stages 3–5, although it is impor-
tant to recognize that stages 1 and 2 can only be deﬁ  ned if there is other evidence of 
kidney damage such as urinary sediment abnormalities (proteinuria and or hematuria) 
or structural abnormalities.
Knowledge of a patient’s GFR allows the dosing of any drug which relies on a renal 
route of excretion to be adjusted appropriately and in addition requires those drugs 
with predictable adverse effects on renal function to be avoided when renal function 
is already poor. Although a number of techniques for the accurate measurement of 
GFR have been described, in practice, these are expensive and complex to perform, 
requiring infusions of appropriate chemical or radiolabeled substances (such as inulin 
of EDTA) and multiple blood sampling. Thus, such techniques remain essentially a 
research tool and are not used in clinical practice. Clearance of endogenous creatinine 
(Creatinine Clearance) is can be used as a surrogate marker of GFR since creatinine is Therapeutics and Clinical Risk Management 2007:3(5) 970
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mainly handled by glomerular ﬁ  ltration. However it requires 
the collection of timed urine samples (usually 24 hours) 
with simultaneous blood sampling and is time consuming to 
perform and often difﬁ  cult for the patient to perform accu-
rately. In addition at low GFRs the contribution of tubular 
and extrarenal excretion of creatinine to the measurement 
becomes signiﬁ  cant and leads to Creatinine Clearance sig-
niﬁ  cantly overestimating GFR. It should also be noted that 
even so called “gold standard” measurements of GFR can 
have up to a 20% day to day variability.
In routine clinical practice, clinicians have relied on 
serum creatinine to assess renal function. However the 
serum creatinine level depends on only on renal function 
but also on muscle mass since creatinine is derived from 
muscle creatine. It cannot therefore, in isolation, accurately 
reﬂ  ect the kidney function of an individual. For a given level 
of renal function, serum creatinine will vary according to 
factors such as age, sex, body mass and ethnic origin since 
these are surrogate markers of an individual’s muscle mass. 
Thus an elderly female with signiﬁ  cant CKD (stage 3) may 
still have a creatinine in the “normal range” because of low 
muscle mass and low creatinine production.
Since the measurement of GFR is not practical for routine 
clinical use, many specialist renal and pathology societies 
including those in the US, UK and Australasia now recom-
mend the adoption of automated reporting of formula based 
estimations of GFR (estimated GFR or eGFR). It should 
always be remembered that such equations are derived from 
studies of typical populations and therefore may have their 
limitations when applied to individuals in whom creatinine 
production is atypical or in whom the volume of distribution 
of creatinine concentration may be altered (see Table 2). They 
may show decreased accuracy in patients with high GFRs 
(eg, the young healthy) and in the elderly and in children. It 
is also particularly important to remember that eGFR was 
validated as a measure of renal function in patients with stable 
chronic kidney disease and therefore should not be used to 
assess of renal function in acutely unwell patients with acute 
kidney injury or changing renal function. However with these 
caveats in mind, the inaccuracies inherent in eGFR are still 
likely to be less than when using serum creatinine alone.
The widespread introduction of automated eGFR report-
ing has made the true prevalence of CKD readily apparent 
to clinicians. Whilst this was the intention, concern has been 
expressed that because of the potential for formulae to under-
perform when the true GFR is near normal and at extremes of 
age, normal elderly patients may be inappropriately labeled 
with a chronic disease. In areas where automated eGFR 
reporting has been introduced nephrology units generally 
experience a signiﬁ  cant increase in referrals; however with 
time once the wave of newly discovered patients have been 
seen, new incident referral rates tend to fall back to baseline 
especially when clinical guidelines which deﬁ  ne those likely 
to beneﬁ  t from nephrology advice are rigorously applied (for 
example the UK Guidelines for Identiﬁ  cation, Management 
and Referral of adults with CKD).
A number of such formulae are available (at least 46) but 
for adults the abbreviated MDRD formula (Levy 2000) has 
been most widely adopted since it is the most practical rely-
ing only on creatinine, age and sex in the calculation. This 
allows it to be reported automatically by laboratories when 
serum creatinine is requested, without additional information 
or measurements being required (the clinician is required to 
apply a correction of 1.21 if the patient is of black African 
extraction). The MDRD formula has been shown to perform 
well in a number of studies of different patient populations 
and typically outperforms other formulae when compared to 
“gold standard” measures of GFR. To improve accuracy of 
the MDRD formula and allow comparison between results 
generated in different laboratories it is important that the 
creatinine assay has been standardised to that used by those 
who developed the MDRD equation (or an appropriate 
Table 1 The stages of CKD as deﬁ  ned in the KDOQI classiﬁ  ca-
tion. CKD is deﬁ  ned as either kidney damage of a GFR of less 
than 60 ml/min/1.73 m2 for more than 3 months
Stage GFR  Description
1   = 90  Kidney damage with normal or
   increased  eGFR
2  60–89  Kidney damage with mild eGFR
   fall
3  30–59  Moderate fall in eGFR
4  15–29  Severe fall in eGFR
5  15 or renal replacement  Established renal failure
   therapy
Table 2 Situations in which creatinine production or volume of 
distribution may be atypical and hence eGFR be unreliable
•  Muscle wasting disease states
• Amputees
• Malnourished  patients
• Edematous  states
• Pregnancy
•  High or low dietary intake of creatinine or creatine
•  Extremes of body size
•  Extremes of age
•  Particular ethnic groupsTherapeutics and Clinical Risk Management 2007:3(5) 971
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correction applied). Many national quality assurance schemes 
for pathology are undertaking such standardization ensuring 
the MDRD formula is appropriately corrected for different 
local creatinine assays; for these reasons automated report-
ing of eGFR is to be preferred rather than the clinician 
calculating eGFR from the reported creatinine. The MDRD 
formula typically underestimates GFR in patients with higher 
levels of kidney function, but such a bias is less important 
when monitoring patients with impaired renal function. It 
is important to remember that the MDRD formula has only 
been validated in adults and that alternative formulae must 
be used for children (of which the Schwartz and Counahan-
Barratt equations are examples).
There are a number of methodological differences 
between the various formulae. For example the MDRD for-
mula was derived by comparison with measured GFR and 
reports eGFR corrected for body surface area where as the 
Cockcroft and Gault formula was derived from creatinine 
clearance and is not corrected for body surface area. Most 
drug information sheets recommend drug dosage adjustment 
based on creatinine clearance, without ‘normalisation’ for 
body surface area: thus use of normalised formulae could lead 
to prescription of inappropriately higher doses for smaller 
patients. However, it is unlikely that such differences would 
result in clinically important differences in drug doses in 
stage 3 CKD. In situations where dosing accuracy is more 
critical (when prescribing chemotherapeutic agents for 
example) sound clinical judgement must be applied and the 
use of formula to adjust drug doses individualised based on 
the best available source of evidence; where necessary direct 
measurement of the GFR should be undertaken.
Prescribing guidelines and drug information leaﬂ  ets 
recommend dose adjustment in renal impairment for drugs 
which are either excreted or metabolized by the kidney. For 
drugs with either minor or no dose related side effects any 
required dose manipulation may be small. Others, especially 
those with potential for nephrotoxicity may need to be 
avoided altogether in advanced kidney disease. However, 
despite the changes in nephrology practice with the adop-
tion of the widely accepted KDOQI classiﬁ  cation of CKD, 
many formularies continue to recommend dose adjustment 
according to arbitrary grades of renal impairment (mild, 
moderate, severe) or serum creatinine levels. The advent 
of eGFR reporting has the potential to allow the clinician 
to adopt a more logical and accurate approach to the use of 
drugs in patients with CKD and in particular has the potential 
to unmask signiﬁ  cant renal impairment in groups of patients 
where it might previously have gone unnoticed as the serum 
creatinine was within or nearly within the “normal range”. 
eGFR is not a perfect solution as it is an estimate based on 
population averages: as such there will still be some situa-
tions where actual assessment of GFR would be preferable 
(especially when using drugs with a high potential for toxicity 
and narrow therapeutic range).
Some practical examples of how eGFR may help improve 
medicines management are listed below.
1.  A number of drugs are best avoided completely in patients 
with CKD because of their predictable adverse effects. The 
commonest example is NSAIDs which have the potential 
to decrease GFR by removing the inﬂ  uence vasodilator 
prostaglandins from within the kidney. If the GFR is near 
normal this may be of little or no clinical signiﬁ  cance. 
However, in patients advanced CKD (certainly stage 4 and 
non dialysis dependent stage 5) the prescription of NSAIDs 
should be avoided. Yet most nephrologists will have seen 
patients precipitated onto dialysis at least in part due to 
inadvertent prescription of a NSAID to a patient who had 
unrecognized advanced CKD. Such an adverse event may 
be particularly likely when the NSAID is prescribed to a 
patient with CKD who has co-existent volume depletion, 
heart failure or sepsis. Automated eGFR reporting may 
help avoid this unmasking the true degree of renal impair-
ment. In addition if it were linked to an “intelligent” com-
puter aided prescribing system, the clinician attempting to 
prescribe a NSAID to a patient with advanced CKD could 
have it automatically ﬂ  agged that such a prescription might 
be undesirable. Then if after careful risk beneﬁ  t assessment 
a NSAID were to be prescribed careful monitoring of renal 
function could be undertaken.
2.  Some drugs should be discontinued if they adversely 
affect renal function. Angiotensin converting enzyme 
inhibitors (ACEis) and Angiotensin receptor blockers 
(ARBs) fall in to this category. ACEis and ARBs may 
result in an unacceptable fall in GFR in patients with 
renal artery stenosis and if it occurs should prompt fur-
ther investigation for this condition. Traditionally advice 
about ACEi and ARB usage has been given in terms or 
arbitrary changes in serum creatinine levels. However a 
more logical approach is to suggest discontinuation of the 
drug and/or referral for further investigation if a certain 
percentage fall in estimated GFR occurs after initiation or 
dose increase (>15% may be an appropriate threshold).
3.  The prescribing advice for some drugs suggests they 
should be avoided if the patient has a serum creatinine 
value above a certain value. As outlined previously 
this will not produce a consistent approach as a given Therapeutics and Clinical Risk Management 2007:3(5) 972
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serum creatinine level could reﬂ  ect differing levels of 
renal function depending on the patient’s age, sex and 
race. For example in the UK the National formulary and 
professional advisory bodies state that “Metformin is 
contraindicated in people with renal impairment (serum 
creatinine greater than 130 µmol/L.)”. However, a serum 
creatinine of 130 µmol/L. in a 60 year old white female 
would equate to an eGFR of 37 ml/min/1.73 m2 and 
CKD stage 3. However the same creatinine in a 20 year 
old black man equates to an eGFR of double that at 79 
ml/min/1.73 m2 and CKD stage 2. Thus by adopting an 
arbitrary cut off for the use of this drug based on creati-
nine has produced an inconsistent result: either one group 
has been potentially deprived of its beneﬁ  ts unnecessarily 
or alternatively (but less likely) another group has been 
exposed to potential toxicity.
4.  A number of drugs require dose adjustment (reduction) 
when renal function is impaired. Many antimicrobials 
fall in to this category. The use of vague terms such as 
“reduce the dose in mild or moderate renal impairment” 
is generally unhelpful to the clinician and leads to an 
inconsistent approach. eGFR offers a more objective 
assessment of the level of renal function and therefore 
the potential to develop clear and consistent guidance for 
the dosing of this group of drugs. There would be reduced 
potential for toxicity, no loss of therapeutic effect and the 
potential for cost savings as a result of reduced does or 
dosing frequencies. Although eGFR has its own incon-
sistencies it is sufﬁ  ciently robust to be used in practice 
for any drug with a broad therapeutic window and few 
dose related side effects.
In conclusion eGFR reporting offers considerable advan-
tages to the prescribing clinician. It provides for the ﬁ  rst time 
a simple, easily understood and readily available tool to allow 
the identiﬁ  cation and stratiﬁ  cation of patients with CKD. It 
allows a more accurate risk assessment for prescribing in 
CKD patients and a more rational approach to prescribing, 
including appropriate dose adjustment and avoidance of 
potentially toxic drugs. There is an urgent need for national 
prescribing formularies to embrace the KDOQI classiﬁ  ca-
tion of CKD and provide consistent advice about the use of 
drugs at various stages of CKD and levels of eGFR. Such an 
approach may prove invaluable in improving prescribing in 
CKD and avoiding drug toxicity in this group of patients.
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